Recent Updates
Recently added Catalysts
ARCT Positive Sentiment

Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration

Key Takeaway: Arcturus Therapeutics announced a $50 million investment from Meiji Seika Pharma, marking an expansion of their collaboration. The investment is at an 80% premium and includes a memorandum of understanding focused on pandemic preparedness in Japan. This partnership aims to enhance the development of liver and respiratory therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Meiji Seika Pharma invests $50 million in Arcturus.
  • Investment comes at an 80% premium.
  • Partnership focuses on pandemic preparedness in Japan.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+165%
120-day peak, hindsight
Typical move
4.4%
average across 6 past catalysts
Cash runway
~80 mo
Minimal dilution risk
Lead asset
ARCT-2303
Phase 3 · COVID-19

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced an expanded collaboration with Meiji Seika Pharma Co., Ltd. (“Meiji”), including a $50 million equity investment at an 80% premium. The expanded partnership includes a memorandum of understanding (“MOU”) related to pandemic preparedness and response in Japan and an exclusive

Frequently Asked Questions

What is the amount of investment from Meiji Seika?

Meiji Seika Pharma invested $50 million in Arcturus Therapeutics.

What premium was offered for the investment?

The investment was made at an 80% premium.

What is the focus of the expanded collaboration?

The collaboration focuses on pandemic preparedness in Japan.

What type of company is Arcturus Therapeutics?

Arcturus is a messenger RNA medicines company.

Last updated: Nov 16, 2026